Finch Therapeutics Raises $53 Million to Advance Microbiome-Based Therapies for Recurrent C. Difficile, Autism and other Disease Areas
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced on 8/27/19 the completion of a $53 million Series C financing.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,